Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejim.2021.01.016 http://scihub22266oqcxt.onion/10.1016/j.ejim.2021.01.016 33581979!7862887!33581979     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+J+Intern+Med 2021 ; 86 (ä): 34-40 Nephropedia Template TP {{tp|p=33581979|t=2021. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies |pdf=|usr=}}{{33581979}} gab.com Text Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies JO: Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33581979 #FOAvip INTRODUCTION: Severe COVID-19 cases have a detrimental hyper-inflammatory host response and different cytokine-blocking biologic agents were explored to improve outcomes. Anakinra blocks the activity of both IL-1alpha and IL?1beta and is approved for different autoinflammatory disorders, but it is used off-label for conditions characterized by an excess of cytokine production. Several studies on anakinra in COVID-19 patients reported positive effects. We performed a meta-analysis of all published evidence on the use of anakinra in COVID19 to investigate its effect on survival and need for mechanical ventilation. METHODS: We searched for any study performed on adult patients with acute hypoxemic failure related to 2019-nCoV infection, receiving anakinra versus any comparator. Primary endpoint was mortality at the longest available follow-up. Adverse effects, need for mechanical ventilation and discharge at home with no limitations were also analysed. RESULTS: Four observational studies involving 184 patients were included. Overall mortality of patients treated with anakinra was significantly lower than mortality in the control group (95% CI 0.14-0.48, p<0.0001). Moreover, patients treated with anakinra had a significantly lower risk of need for mechanical ventilation than controls (95% CI 0.250.74, p=0.002). No difference in adverse events and discharge at home with no limitations was observed. The Trial Sequential Analysis z-cumulative line reached the monitoring boundary for benefit and the required sample size. CONCLUSIONS: Administration of anakinra in COVID-19 patients was safe and might be associated with reductions in both mortality and need for mechanical ventilation. Randomized clinical trials are warranted to confirm these findings. Twit Text FOAVip Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies ????Eur J Intern Med http://www.kidney.de/pget.php?&tw=1&pmid=33581979 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33581979 #FOAvip English Wikipedia <ref>{{Cite pmid|33581979}}</ref> Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies #MMPMID33581979 Pasin L; Cavalli G; Navalesi P; Sella N; Landoni G; Yavorovskiy AG; Likhvantsev VV; Zangrillo A; Dagna L; Monti G Eur J Intern Med 2021[Apr]; 86 (ä): 34-40 PMID33581979show ga INTRODUCTION: Severe COVID-19 cases have a detrimental hyper-inflammatory host response and different cytokine-blocking biologic agents were explored to improve outcomes. Anakinra blocks the activity of both IL-1alpha and IL?1beta and is approved for different autoinflammatory disorders, but it is used off-label for conditions characterized by an excess of cytokine production. Several studies on anakinra in COVID-19 patients reported positive effects. We performed a meta-analysis of all published evidence on the use of anakinra in COVID19 to investigate its effect on survival and need for mechanical ventilation. METHODS: We searched for any study performed on adult patients with acute hypoxemic failure related to 2019-nCoV infection, receiving anakinra versus any comparator. Primary endpoint was mortality at the longest available follow-up. Adverse effects, need for mechanical ventilation and discharge at home with no limitations were also analysed. RESULTS: Four observational studies involving 184 patients were included. Overall mortality of patients treated with anakinra was significantly lower than mortality in the control group (95% CI 0.14-0.48, p<0.0001). Moreover, patients treated with anakinra had a significantly lower risk of need for mechanical ventilation than controls (95% CI 0.250.74, p=0.002). No difference in adverse events and discharge at home with no limitations was observed. The Trial Sequential Analysis z-cumulative line reached the monitoring boundary for benefit and the required sample size. CONCLUSIONS: Administration of anakinra in COVID-19 patients was safe and might be associated with reductions in both mortality and need for mechanical ventilation. Randomized clinical trials are warranted to confirm these findings. |*COVID-19[MESH] |*Interleukin 1 Receptor Antagonist Protein/therapeutic use[MESH] |Adult[MESH] |Cohort Studies[MESH] |Humans[MESH] |Respiration, Artificial[MESH] |SARS-CoV-2[MESH]Anakinra for patients with COVID-19: a meta-analysis of non-randomized(epmc).pdf DeepDyve Pubget Overpricing